Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4396
Source ID: NCT05706506
Associated Drug: Tirzepatide
Title: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
Acronym:
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT05706506/results
Conditions: Type 2 Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: Tirzepatide
Outcome Measures: Primary: Change From Baseline in Hemoglobin A1c (HbA1c), HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time., Baseline, Week 12 | Secondary: Change From Baseline in Percentage of Time Per Day That Continuous Glucose Monitoring (CGM)-Derived Values Were >180 Milligram/Deciliter (mg/dl) (10 Millimole/Liter (mmol/L)), Change from Baseline in Percentage of Time per Day that CGM-derived Values were \>180 mg/dl (10 mmol/L) was assessed., Baseline, Week 4|Change From Baseline in Percentage of Time Per Day That CGM-derived Values Were >180 mg/dl (10 mmol/L), Change from Baseline in Percentage of Time per Day that CGM-derived Values were \>180 mg/dl (10 mmol/L) was assessed., Baseline, Week 12|Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L), Change from Baseline in Duration of Time in Minutes per Day that CGM derived Values were \>180 mg/dl (10 mmol/L) was assessed., Baseline, Week 4|Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L), Change from Baseline in Duration of Time in Minutes per Day that CGM derived Values were \>180 mg/dl (10 mmol/L) was assessed., Baseline, Week 12|Change From Baseline in Fasting Serum Glucose (FSG), Change from Baseline in FSG was assessed., Baseline, Week 12|Change From Baseline in Weight, Change from Baseline in Weight was assessed., Baseline, Week 12
Sponsor/Collaborators: Sponsor: Eli Lilly and Company
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 152
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2023-03-08
Completion Date: 2023-10-31
Results First Posted: 2024-12-13
Last Update Posted: 2024-12-13
Locations: Fiel Family and Sports Medicine PC, Tempe, Arizona, 85283, United States|New Hope Research Development, Corona, California, 92882, United States|Velocity Clinical Research, Gardena, Gardena, California, 90247, United States|Velocity Clinical Research, Huntington Park, Huntington Park, California, 90255, United States|Velocity Clinical Research, Huntington Park, Los Angeles, California, 90057, United States|Valley Clinical Trials, Inc., Northridge, California, 91325, United States|Dream Team Clinical Research, Pomona, California, 91767, United States|Scripps Whittier Diabetes Institute, San Diego, California, 92121-1520, United States|Metabolic Institute of America, Tarzana, California, 91356-3551, United States|CMR of Greater New Haven, LLC, Waterbury, Connecticut, 06708, United States|Velocity Clinical Research, Hallandale Beach, Hallandale Beach, Florida, 33009, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, 32204, United States|Florida Institute For Clinical Research, LLC, Orlando, Florida, 32825, United States|New Tampa Health, Tampa, Florida, 33603-3402, United States|Georgia Clinical Research, Lawrenceville, Georgia, 30044-5896, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, 30076, United States|Velocity Clinical Research, Valparaiso, Valparaiso, Indiana, 46383, United States|Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, 50265, United States|Cotton O'Neil Clinic, Topeka, Kansas, 66606, United States|Versailles Family Medicine, Versailles, Kentucky, 40383-1947, United States|Endocrine and Metabolic Consultants, Rockville, Maryland, 20852, United States|Clinical Research Professionals, Chesterfield, Missouri, 63005, United States|Clinical Research of South Nevada, Las Vegas, Nevada, 89121, United States|Palm Research Center Tenaya, Las Vegas, Nevada, 89128, United States|Advanced Medical Research, Maumee, Ohio, 43537-9402, United States|Conrad Clinical Research, Edmond, Oklahoma, 73013, United States|Mountain View Clinical Research, Inc., Greenville, South Carolina, 29607, United States|Texas Diabetes & Endocrinology, P.A., Austin, Texas, 78731-4309, United States|North Texas Endocrine Center, Dallas, Texas, 75231, United States|Memorial City Endocrine Consultants, Houston, Texas, 77043-2742, United States|Consano Clinical Research, LLC, Shavano Park, Texas, 78231, United States|ClinPoint Trials, Waxahachie, Texas, 75165, United States
URL: https://clinicaltrials.gov/show/NCT05706506

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress